The current valuation score of Protara Therapeutics Inc is 7.05, ranking 263 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.95, which is -93.77% below the recent high of -0.18 and -84.34% above the recent low of -5.43.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.